After a couple of calls and emails back, I worked out where I missed the mark:
1) My core assumption that Life Sciences investors are interested in reading research, was wrong. They don’t make investments by reading papers and then contacting relevant companies. They network, go to events and are introduced to interesting founders. It’s more relationships than science.
They might do some scientific due diligence, but this doesn’t really go beyond a Google Scholar search.
2) There are some investors who are really clued up on research. But they’re often PhDs/medical doctors themselves. They don’t need a 200-word summary filled with emojis. They can read the research themselves.
3) Even if they did need someone to consolidate the research for them (which they don’t) — they would need different types of information. More like a high-level document summarising the whole field, with tables comparing different interventions.
4) Some of the ballers in Private Equity do outsource scientific due diligence, but they would just pay a Key Opinion Leader — not mess about with paper summaries.